Sarepta’s Duchenne gene therapy gets off to a strong start in sales, as future lies in limbo
Sarepta Therapeutics said it brought in $69 million in sales from its Duchenne muscular dystrophy gene therapy in the first few months the treatment has been available commercially.
Despite the fact that the first dose of the gene therapy, marketed as Elevidys, was delivered in August, it eclipsed two of Sarepta’s other Duchenne treatments in third-quarter sales — Amondys 45 and Vyondys 53. Both of those are exon skipping drugs developed for Duchenne patients with specific mutations.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
